Biothera’s Imprime PGG in combination with cetuximab, carboplatin and paclitaxel has met all the endpoints in a Phase II non small cell lung cancer clinical trial.

Imprime PGG is an immunomodulatory drug, used as a treatment for cancer.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The open label multicentre randomised trial enrolled 90 patients to evaluate the safety and efficacy of Imprime PGG along with cetuximab and a standard chemotherapy regimen (carboplatin and paclitaxel) compared to cetuximab alone with the same chemotherapy.

The aim of the study is to assess the anti-tumour effects of Imprime PGG with cetuximab and standard chemotherapy, based on overall response rate as evaluated by the RECIST trial.

In pre-clinical cancer models, Imprime PGG has been found to reduce tumour growth and enhance long-term survival by killing neutrophils.

Imprime PGG is being investigated in a Phase III trial in KRAS wild-type colorectal cancer and several Phase II clinical trials in non small cell lung cancer and chronic lymphocytic leukaemia.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now